A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma

Nature Communications

Volumn 6, Issue , 2015, Pages

  Wei, Jin Huan ^a   Haddad, Ahmed ^b   Wu, Kai Jie ^c   Zhao, Hong Wei ^d   Kapur, Payal ^e   Zhang, Zhi Ling ^f   Zhao, Liang Yun ^g   Chen, Zhen Hua ^a   Zhou, Yun Yun ^e   Zhou, Jian Cheng ^b   Wang, Bin ^b   Yu, Yan Hong ^g   Cai, Mu Yan ^f   Xie, Dan ^f   Liao, Bing ^a   Li, Cai Xia ^a   Li, Pei Xing ^a   Wang, Zong Ren ^a   Zhou, Fang Jian ^f   Shi, Lei ^d   Liu, Qing Zuo ^d   Gao, Zhen Li ^d   He, Da Lin ^c   Chen, Wei ^a   Hsieh, Jer Tsong ^b   Li, Quan Zhen ^e   Margulis, Vitaly ^b   Luo, Jun Hang ^a   more..

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^g KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CANCER; DATA SET; GENE EXPRESSION; METHYLATION;

CHINA; UNITED STATES;

TUMOR MARKER;

ADULT; AGED; CANCER STAGING; CARCINOMA, RENAL CELL; DNA METHYLATION; FEMALE; GENETICS; HUMAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DNA METHYLATION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84946151605     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9699     Document Type: Article

References (53)

1. Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67, 913-924 (2015).
2. Zigeuner, R. et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur. Urol. 57, 102-109 (2010).
3. Ficarra, V. et al. The Stage, Size, Grade and Necrosis score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int. 103, 165-170 (2009).
4. Brock, M. V. et al. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 358, 1118-1128 (2008).
5. Castelo-Branco, P. et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol. 14, 534-542 (2013).
6. Esteller, M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 4, 351-358 (2003).
7. Sandoval, J. et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J. Clin. Oncol. 31, 4140-4147 (2013).
8. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
9. Ricketts, C. J. et al. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics 7, 278-290 (2012).
10. Lasseigne, B. N. et al. DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Med. 12, 235 (2014).
11. Arai, E. et al. Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int. J. Cancer 135, 1330-1342 (2014).
12. Ibragimova, I. et al. Genome-wide promoter methylome of small renal masses. PLoS ONE 8, e77309 (2013).
13. Kratz, J. R. et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379, 823-832 (2012).
14. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
15. Liu, N. et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 13, 633-641 (2012).
16. Yoon, K. A. et al. Genetic variations associated with postoperative recurrence in stage I non-small cell lung cancer. Clin. Cancer Res. 20, 3272-3279 (2014).
17. Buyse, M. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192 (2006).
18. De Sousa, E. M. F. et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614-618 (2013).
19. Arai, E. et al. Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis 33, 1487-1493 (2012).
20. Simon, R. & Altman, D. G. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer 69, 979-985 (1994).
21. Joseph, F., Hair, J., Anderson, R. E., Tatham, R. L. & Black, W. C. Multivariate Data Analysis, 4th edn (Prentice-Hall, Inc., 1995).
22. Tibshirani, R. The lasso method for variable selection in the Cox model. Stat. Med. 16, 385-395 (1997).
23. Zhang, H. H. & Lu, W. Adaptive Lasso for Coxs proportional hazards model. Biometrika 94, 691-703 (2007).
24. Zhang, J. X. et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 14, 1295-1306 (2013).
25. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
26. Gulati, S. et al. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur. Urol. 66, 936-948 (2014).
27. Barry, W. T. et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J. Clin. Oncol. 28, 2198-2206 (2010).
28. Zhao, H. et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 3, e13 (2006).
29. Kosari, F. et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res. 11, 5128-5139 (2005).
30. Brooks, S. A. et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. 66, 77-84 (2014).
31. Escudier, B. J. et al. Validation of a 16-gene signature for prediction of recurrence after nephrectomy in stage I-III clear cell renal cell carcinoma (ccRCC). ASCO Meeting Abstracts 32, 4502 (2014).
32. Chatterton, Z. et al. Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia. Clin. Chem. 60, 995-1003 (2014).
33. Bell, A., Bell, D., Weber, R. S. & El-Naggar, A. K. CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer 117, 2898-2909 (2011).
34. Milstein, M. et al. RIN1 is a breast tumor suppressor gene. Cancer Res. 67, 11510-11516 (2007).
35. Yamada, S. et al. Identification of twinfilin-2 as a factor involved in neurite outgrowth by RNAi-based screen. Biochem. Biophys. Res. Commun. 363, 926-930 (2007).
36. West, J., Widschwendter, M. & Teschendorff, A. E. Distinctive topology of age-associated epigenetic drift in the human interactome. Proc. Natl Acad. Sci. USA 110, 14138-14143 (2013).
37. Cheng, C. P. et al. Network-based analysis identifies epigenetic biomarkers of esophageal squamous cell carcinoma progression. Bioinformatics 30, 3054-3061 (2014).
38. Dick, K. J. et al. DNA methylation and body-mass index: a genome-wide analysis. Lancet 383, 1990-1998 (2014).
39. Assenov, Y. et al. Comprehensive analysis of DNA methylation data with RnBeads. Nat. Methods 11, 1138-1140 (2014).
40. Teschendorff, A. E. et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics 29, 189-196 (2013).
41. Triche, Jr T. J., Weisenberger, D. J., Van Den Berg, D., Laird, P. W. & Siegmund, K. D. Low-level processing of Illumina Infinium DNA Methylation BeadArrays. Nucleic Acids Res. 41, e90 (2013).
42. Price, M. E. et al. Additional annotation enhances potential for biologicallyrelevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin 6, 4 (2013).
43. Chen, Y. A. et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 8, 203-209 (2013).
44. Gentleman, R., Carey, V., Huber, W., Irizarry, R. & Dudoit, S. Bioinformatics and Computational Biology Solutions Using R and Bioconductor (Statistics for Biology and Health) (Springer-Verlag, Inc., 2005).
45. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
46. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
47. Camp, R. L., Dolled-Filhart, M. & Rimm, D. L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10, 7252-7259 (2004).
48. Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R. Stat. Soc. Ser. B 58, 267-288 (1996).
49. Goeman, J. J. L1 penalized estimation in the Cox proportional hazards model. Biom. J. 52, 70-84 (2010).
50. Gui, J. & Li, H. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics 21, 3001-3008 (2005).
51. Sveen, A. et al. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin. Cancer Res. 18, 6001-6010 (2012).
52. Olk-Batz, C. et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 117, 4871-4880 (2011).
53. Kohavi, R. In Proceedings of the 14th International Joint Conference on Artificial Intelligence, Vol 2 (Morgan Kaufmann Publishers Inc., 1995).